About this Research Topic
Lung cancer is a leading cause of cancer death in the United States. It is usually managed through a multi-modality treatment strategy. The five-year relative survival rate of all lung cancer patients continuously improved from 10.7% in 1972 to 19.8% in 2010. This is mainly due to improvements in screening, staging, surgical management, systemic therapy such as chemotherapy and immunotherapy and advances in radiation delivery techniques. Among all treatment options, radiotherapy (RT) is the only modality for which there is indication in all stages of cancer. Stereotactic body radiation therapy (SBRT), is safely and effectively delivered to patients with inoperable early-stage disease, including those with poor pulmonary function at baseline and has been shown that may lead to better overall survival compared to surgery in patients with operable disease. RT is also given concurrently or sequentially with chemotherapy in patients with locally advanced disease. In the recent years, there has been an increasing interest to combine RT or chemoradiation with targeted therapy such as immunotherapy.
RT is mainly limited by radiation-induced toxicity in organs such as lung, heart, esophagus, chest-wall, airways, etc. Studies have shown that sequential or concurrent use of RT with other treatment modalities may also increase the radiation-induced toxicity synergistically. The most common strategy currently used in clinics to manage the radiation-induced toxicity is to identify and score the toxicity, form a multi-disciplinary team to consider the patient’s health, disease status and comorbidities, and find the best personalized approach. Radiation-induced toxicity could be life threatening in cases such as cardiopulmonary toxicity and some cases of radiation-induced pneumonitis, and can adversely affect the treatment outcome. Therefore, strategies to minimize the risk of radiation-induced toxicity are a key factor for the success of RT and are of great interest.
In this Research Topic, we invite all authors to submit their recent findings in minimizing radiation-related toxicity when managing thoracic malignancies. We welcome original research, clinical trials, basic and pre-clinical research and meta-analyses on the following topics:
• Recent advances in dose-response or predictive models to forecast acute and late toxicity;
• Application of functional imaging including PET/CT, MRI, etc. to develop imaging biomarkers for outcome prediction, toxicity assessment and functional based treatment adaptation;
• Advances in imaging for motion and respiratory management;
• Recent advances in FLASH or Grid radiotherapy;
• Recent advances in particle therapy;
• Genomically adjusted radiation dosing.
Please note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Please note the following conflict of interest disclosure:
Mohammad Rezaee - Loyalty from Xstrahl Inc for the SARRP-FLASH system.
RT is mainly limited by radiation-induced toxicity in organs such as lung, heart, esophagus, chest-wall, airways, etc. Studies have shown that sequential or concurrent use of RT with other treatment modalities may also increase the radiation-induced toxicity synergistically. The most common strategy currently used in clinics to manage the radiation-induced toxicity is to identify and score the toxicity, form a multi-disciplinary team to consider the patient’s health, disease status and comorbidities, and find the best personalized approach. Radiation-induced toxicity could be life threatening in cases such as cardiopulmonary toxicity and some cases of radiation-induced pneumonitis, and can adversely affect the treatment outcome. Therefore, strategies to minimize the risk of radiation-induced toxicity are a key factor for the success of RT and are of great interest.
In this Research Topic, we invite all authors to submit their recent findings in minimizing radiation-related toxicity when managing thoracic malignancies. We welcome original research, clinical trials, basic and pre-clinical research and meta-analyses on the following topics:
• Recent advances in dose-response or predictive models to forecast acute and late toxicity;
• Application of functional imaging including PET/CT, MRI, etc. to develop imaging biomarkers for outcome prediction, toxicity assessment and functional based treatment adaptation;
• Advances in imaging for motion and respiratory management;
• Recent advances in FLASH or Grid radiotherapy;
• Recent advances in particle therapy;
• Genomically adjusted radiation dosing.
Please note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Please note the following conflict of interest disclosure:
Mohammad Rezaee - Loyalty from Xstrahl Inc for the SARRP-FLASH system.
Keywords: Lung cancer, radiotherapy, outcome and toxicity assessment, predictive modeling, functional imaging, FLASH, GRID, genetically-driven
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
